Publications

The pharmaceutical industry contributes greatly to the quality of life and prosperity of the Swiss population. Companies invest more than CHF 7 billion annually in research and development in Switzerland. However, the study published today also makes it clear that Switzerland cannot simply rest on its success of recent years.

The things that help the patients of today are crucial to the future of Switzerland as a pharmaceutical location. The Annual Report 2025 shows how medical advances, security of supply and economic strength are connected – and the direction that politics now needs to take.

The Innovation Report 2025 presents the latest drug approvals in Switzerland, key research trends and the tangible benefits of innovative therapies for patients and the healthcare system.